H. Shimada, Terminology and morphologic criteria of neuroblastic tumors, Cancer, vol.25, issue.2, pp.349-63, 1999.
DOI : 10.1002/(SICI)1097-0142(19991101)86:9<1657::AID-CNCR6>3.3.CO;2-A

S. Cohn, The International Neuroblastoma Risk Group (INRG) 916 classification system: an INRG Task Force report, J Clin Oncol, vol.917, pp.27289-97, 2009.

I. Janoueix-lerosey, Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma, Journal of Clinical Oncology, vol.27, issue.7, pp.1026-1059, 2009.
DOI : 10.1200/JCO.2008.16.0630

URL : https://hal.archives-ouvertes.fr/inserm-00369944

A. Canete, Poor survival for infants with MYCN-amplified metastatic 921 neuroblastoma despite intensified treatment: the International Society of 922 Paediatric Oncology European Neuroblastoma Experience, J Clin Oncol, vol.92327, pp.1014-1023, 2009.

E. Attiyeh, Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma, New England Journal of Medicine, vol.353, issue.21, pp.2243-53, 2005.
DOI : 10.1056/NEJMoa052399

G. Brodeur, International criteria for diagnosis, staging, and 927 response to treatment in patients with neuroblastoma, J Clin Oncol, vol.9286, pp.1874-81, 1988.

G. Brodeur, Revisions of the international criteria for neuroblas- 930 toma diagnosis, staging and response to treatment, Prog Clin Biol Res, vol.931385, pp.363-372, 1994.

H. Brisse, Guidelines for imaging and staging of neuroblastic 933 tumors: consensus report from the International Neuroblastoma Risk 934 Group Project Criteria for evaluation of disease extent by (123)I- 936 metaiodobenzylguanidine scans in neuroblastoma: a report for the Inter- 937 national Neuroblastoma Risk Group (INRG) Task Force, Radiology Br J Cancer, vol.26110102, issue.93811, pp.243-57, 2010.

G. Cecchetto, Surgical risk factors in primary surgery for localized 943 neuroblastoma: the LNESG1 study of the European International Society 944 of Pediatric Oncology Neuroblastoma Group Somatic and germline activating mutations of 947 the ALK kinase receptor in neuroblastoma Emergence of new ALK mutations at relapse of 949 neuroblastoma Activated Alk triggers prolonged neurogenesis and Ret 951 upregulation providing a therapeutic target in ALK-mutated neuroblas- 952 toma 953 [16] Taieb D, et al. EANM 2012 guidelines for radionuclide imaging of 954 phaeochromocytoma and paraganglioma Radiochemistry, biochemistry, and kinetics of 131I- 957 metaiodobenzylguanidine (MIBG) and 123 I-MIBG: clinical implications 958 of the use of 123 I-MIBG, Troncone L, Rufini V. MIBG in diagnosis of neuroendocrine tumors. 960 Nuclear Medicine in Clinical Diagnosis and Treatment, pp.1027-1060, 1987.

M. Lynn, Portrayal of pheochromocytoma and normal human 963 adrenal medulla by m-[ 123 I]iodobenzylguanidine: concise communica- 964 tion Refining interpretation of MIBG scans in children Guidelines for radioiodinated MIBG scintigraphy in 968 children Combining 123 I-metaiodobenzylguanidine 970 SPECT/CT and 18 F-FDG PET/CT for the assessment of brown adipose 971 tissue activity in humans during cold exposure Bombardieri E, et al. 131 I/ 123 I-metaiodobenzylguanidine (mIBG) scinti- 974 graphy: procedure guidelines for tumour imaging, Linvingstone J Nucl Med J Nucl 966 Med Eur J Nucl Med Mol Imaging J Nucl Med Eur J Nucl Med Mol 975 Imaging J Nucl Med, vol.252035213022233717, issue.54, pp.13-962436, 0980.

C. Madre, Hypertension in Childhood Cancer, Journal of Pediatric Hematology/Oncology, vol.28, issue.10, pp.659-64, 2006.
DOI : 10.1097/01.mph.0000212995.56812.bb

M. Biermann, Is there a role for PET-CT and SPECT-CT in pediatric oncology?, Acta Radiologica, vol.51, issue.9, pp.1037-1082, 2013.
DOI : 10.2967/jnumed.110.075390

K. Rozovsky, Added value of SPECT/CT for correlation of MIBG 985 scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma, p.986

M. Wartski, Post-surgical 123 I-MIBG SPECT/CT in neuroblastoma, p.988

H. Goo, Whole-body MRI of neuroblastoma, European Journal of Radiology, vol.75, issue.3, pp.306-320, 2010.
DOI : 10.1016/j.ejrad.2009.09.014

H. Nadel and . Spect, CT in pediatric patient management, Eur J Nucl Med, vol.992
DOI : 10.1007/s00259-014-2697-7

B. Decarolis, Iodine-123 metaiodobenzylguanidine scintigraphy 994 scoring allows prediction of outcome in patients with stage 4, p.995

G. Yanik, Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group, Journal of Nuclear Medicine, vol.54, issue.4, pp.541-549, 2013.
DOI : 10.2967/jnumed.112.112334

E. Bombardieri, Nuclear medicine imaging of neuroendocrine 1001 tumours, Annals of Oncology, vol.12, issue.2suppl, pp.51-61, 2001.
DOI : 10.1023/A:1012488727716

J. Lumbroso, Sensitivity and specificity of meta-iodobenzylguanidine 1003 (mIBG) scintigraphy in the evaluation of neuroblastoma: analysis of 1004

A. Leung, Specificity of radioiodinated MIBG for neural crest tumors 1006 in childhood, J Nucl Med, vol.38, pp.1352-1359, 1997.

T. Vik, 123)I-mIBG scintigraphy in patients with known or 1008 suspected neuroblastoma: results from a prospective multicenter trial, 1009.

S. Carlin, Development of a real-time polymerase chain reaction 1011 assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by 1012 neuroblastoma tumors, Clin Cancer Res, vol.9, pp.3338-3382, 2003.

K. Matthay, Central nervous system metastases in neuroblastoma, Cancer, vol.17, issue.Suppl 1, pp.155-65, 2003.
DOI : 10.1002/mpo.2950170114

W. Fendler, High 123I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology, European Journal of Nuclear Medicine and Molecular Imaging, vol.353, issue.11, pp.1701-1711, 1018.
DOI : 10.1056/NEJMoa052399

W. Fendler, Combined scintigraphy and tumor marker analysis 1020 predicts unfavorable histopathology of neuroblastic tumors with high 1021 accuracy, PLoS One, vol.10, pp.132809-1022, 2015.

D. Taggart, F]Fluorodeoxyglucose Positron Emission Tomography to Evaluate Response After Iodine-131 MIBG Therapy for Relapsed Neuroblastoma, Journal of Clinical Oncology, vol.27, issue.32, pp.5343-5352, 2009.
DOI : 10.1200/JCO.2008.20.5732

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773221

W. Mueller, E. Coppenrath, and T. Pfluger, Nuclear medicine and multimo- 1030 dality imaging of pediatric neuroblastoma, Pediatr Radiol, vol.43, pp.1031-418, 2013.
DOI : 10.1007/s00247-012-2512-1

R. Boellaard, FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0, European Journal of Nuclear Medicine and Molecular Imaging, vol.28, issue.10, pp.328-54, 2015.
DOI : 10.1097/MNM.0b013e3282eff2d5

URL : https://link.springer.com/content/pdf/10.1007%2Fs00259-014-2961-x.pdf

J. Stauss, Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology, European Journal of Nuclear Medicine and Molecular Imaging, vol.34, issue.Suppl 2, pp.1581-1589, 2008.
DOI : 10.1007/s00259-008-0826-x

F. Montravers, Guide pour la rédaction de protocoles pour la 1037

L. Uslu, Value of 18 F-FDG PET and PET/CT for evaluation of 1041

B. Shulkin, Neuroblastoma, p.1044
DOI : 10.1007/0-387-34641-4_13

H. Melzer, 123I-MIBG scintigraphy/SPECT versus 18F-FDG PET in paediatric neuroblastoma, European Journal of Nuclear Medicine and Molecular Imaging, vol.75, issue.9, pp.1648-58, 1047.
DOI : 10.1016/j.ejrad.2009.09.014

M. Breton, Imagerie fonctionnelle et métabolique du neuroblastome en 2016 Extending positron emission tomography scan utility to 1049 high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emis- 1050 sion tomography as sole imaging modality in follow-up of patients 1052 [52] Sharp SE, et al. 123 I-MIBG scintigraphy and 18 F-FDG PET in neuro- 1053 blastoma, Médecine Nucléaire J Clin Oncol J Nucl Med, vol.1950, pp.3397-4051237, 1051.

Y. Choi, 18)F-FDG PET as a single imaging modality in pediatric 1055 neuroblastoma: comparison with abdomen CT and bone scintigraphy, 1056.

J. Lee, Prognostic value of pretreatment FDG PET in pediatric 1058 neuroblastoma 1059 [55] Minn H, et al. 18 F-FDOPA: a multiple-target molecule, 56] Piccardo A, et al. Comparison of 18 F-dopa PET/CT and 123 I-MIBG 1062 scintigraphy in stage 3 and 4 neuroblastoma: a pilot study, pp.304-317, 1063.

O. Aupee, Guide pour la rédaction de protocoles pour la tomographie 1065 par émission de positons (TEP) à la 6-fluoro-[ 18 F]-L-dihydroxyphényla- 1066 lanine ou 6-fluoro-[ 18 F]-L-DOPA ([ 18 F]-FDOPA) Société française de 1067 médecine nucléaire; 2010. 1068 [58] Piccardo A, et al. Prognostic value of (1)(8)F-DOPA PET/CT at the time of 1069 recurrence in patients affected by neuroblastoma Weak uptake of 123 I-MIBG and 18 F-FDOPA contrasting 1072 with high 18 F-FDG uptake in stage I neuroblastoma, Eur J Nucl Med Mol Imaging Clin Nucl Med, vol.4140, pp.1046-56, 1070.

E. Lopci, 18F-DOPA PET/CT in Neuroblastoma, Clinical Nuclear Medicine, vol.37, issue.4, pp.73-81, 2012.
DOI : 10.1097/RLU.0b013e3182485172

A. Kroiss, Functional imaging in phaeochromocytoma and neuro- 1077 blastoma with 68 Ga-DOTA-Tyr 3-octreotide positron emission tomogra, p.1078
DOI : 10.1007/s00259-010-1720-x

G. Kong, Initial experience with gallium-68 DOTA-octreotate PET/ 1081 CT and peptide receptor radionuclide therapy for pediatric patients with 1082 refractory metastatic neuroblastoma, Q3 J Pediatr Hematol Oncol, 1083.
DOI : 10.1097/mph.0000000000000411

URL : http://pdfs.journals.lww.com/jpho-online/2016/03000/Initial_Experience_With_Gallium_68_DOTA_Octreotate.1.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1504812623778;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzd6LC49CeETXf/FxQ/t3Dx/s0lk45hO4gVLKrc2xSuiVZmUZBrul9gk8p2IKfLPfLj;hash|AfxWAR5za0TtXy34x2HBkg==

M. Dumba, N. Jawad, and K. Mchugh, Neuroblastoma and nephroblastoma: a radiological review, Cancer Imaging, vol.68, issue.7, pp.5-1085, 2015.
DOI : 10.1016/j.crad.2012.11.012

URL : https://cancerimagingjournal.biomedcentral.com/track/pdf/10.1186/s40644-015-0040-6?site=cancerimagingjournal.biomedcentral.com

J. Gains, 177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma, Journal of Nuclear Medicine, vol.52, issue.7, pp.1041-1048, 2011.
DOI : 10.2967/jnumed.110.085100

H. Zhang, Imaging the norepinephrine transporter in neuroblastoma: 1088 a comparison of [ 18 F]-MFBG and 123 I-MIBG, Clin Cancer Res, vol.20, pp.1089-2182, 1090.

S. Huang, Patient-Specific Dosimetry Using Pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) Dynamic PET/CT Imaging Before [131I]mIBG Targeted Radionuclide Therapy for Neuroblastoma, Molecular Imaging and Biology, vol.42, issue.2, pp.284-94, 2015.
DOI : 10.1109/JPROC.2009.2032855

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336853

A. Cistaro, 124 I-MIBG: a new promising positron-emitting radio- 1095 pharmaceutical for the evaluation of neuroblastoma, Nucl Med Rev Cent, 1096.

. Pour and M. Breton, Imagerie fonctionnelle et métabolique du neuroblastome en 2016, Médecine Nucléaire, 2016.